Non-medical reverse switch between the originator infliximab and its biosimilar in patients with inflammatory bowel disease: clinical outcomes and therapeutic drug monitoring

被引：0
|
作者：
Gonczi, L. [1 ]
Ilias, A. [1 ]
Szanto, K. [2 ]
Kurti, Z. [1 ]
Golovics, P. A. [3 ]
Farkas, K. [2 ]
Schafer, E. [3 ]
Szepes, Z. [2 ]
Szalay, B. [4 ]
Vincze, A. [5 ]
Szamosi, T. [3 ]
Molnar, T. [2 ]
Lakatos, P. [6 ]
机构：
[1] Semmelweis Univ, Dept Internal Med 1, Budapest, Hungary
[2] Univ Szeged, Dept Med 1, Szeged, Hungary
[3] Mil Hosp, State Hlth Ctr, Dept Gastroenterol, Budapest, Hungary
[4] Semmelweis Univ, Dept Lab Med, Budapest, Hungary
[5] Univ Pecs, Dept Med 1, Pecs, Hungary
[6] McGill Univ, Div Gastroenterol, Hlth Ctr, Montreal, PQ, Canada
来源：
JOURNAL OF CROHNS & COLITIS | 2019年 / 13卷
关键词：
D O I：
10.1093/ecco-jcc/jjy222.533
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P409
引用
收藏
页码：S314 / S314
页数：1
相关论文
共 50 条
  • [31] Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations
    Sieczkowska, J.
    Jarzebicka, D.
    Banaszkiewicz, A.
    Plocek, A.
    Gawronska, A.
    Toporowska-Kowalska, E.
    Oracz, G.
    Meglicka, M.
    Kierkus, J.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (02): : 127 - 132
  • [32] A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
    Glintborg, Bente
    Sorensen, Inge Juul
    Loft, Anne Gitte
    Lindegaard, Hanne
    Linauskas, Asta
    Hendricks, Oliver
    Hansen, Inger Marie Jensen
    Jensen, Dorte Vendelbo
    Manilo, Natalia
    Espesen, Jakob
    Klarlund, Mette
    Grydehoj, Jolanta
    Dieperink, Sabine Sparre
    Kristensen, Salome
    Olsen, Jimmi Sloth
    Nordin, Henrik
    Chrysidis, Stavros
    Pedersen, Dorte Dalsgaard
    Sorensen, Michael Veedfald
    Andersen, Lis Smedegaard
    Gron, Kathrine Lederballe
    Krogh, Niels Steen
    Pedersen, Lars
    Hetland, Merete Lund
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (08) : 1426 - 1431
  • [33] Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission
    Gros, B.
    Soto Escribano, P.
    Marin Pedrosa, S.
    Medina Medina, R.
    Benitez, J. M.
    Iglesias-Flores, E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I486 - I486
  • [34] Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission
    Gros, B.
    Soto Escribano, P.
    Marin Pedrosa, S.
    Medina Medina, R.
    Benitez, J. M.
    Iglesias-Flores, E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I486 - I486
  • [35] Clinical Outcomes of Therapeutic Drug Monitoring in Inflammatory Bowel Disease
    Reznicek, Emily
    Moafa, Ghady
    Barnette, Brooke
    Montane, Bryce
    Ghouri, Yezaz
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S772 - S772
  • [36] Real-World Outcomes of a Mandatory Adalimumab Non-Medical Biosimilar Switch for Patients With Inflammatory Bowel Disease: A Single Center Retrospective Study
    Hoang, Thomas
    Chen Kiow, Jeremy Liu
    Bedi, Harjot
    Ardekani, Zhina Majdzadeh
    Rosenfeld, Daniel
    Reise-Filteau, Marica
    Bressler, Brian
    Leung, Yvette
    Rosenfeld, Greg
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S748 - S749
  • [37] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab
    Srinivasan, Ashish
    Haifer, Craig
    Thin, Lena
    MEDICAL JOURNAL OF AUSTRALIA, 2021, 215 (09) : 435 - 435
  • [38] Efficacy of Infliximab Biosimilar for Induction and Maintenance Therapy in Inflammatory Bowel Disease After Switch From Drug Originator: A Meta-Analysis
    Kashani, Amir
    Syal, Gaurav
    Bonthala, Nirupama
    McGovern, Dermot P. B.
    David, Shih
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S390 - S390
  • [39] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab
    Lim, David
    Bandiera, Rhiannon
    Handsley, Elizabeth
    MEDICAL JOURNAL OF AUSTRALIA, 2021,
  • [40] Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients
    Fischer, S.
    Klenske, E.
    Schmitt, H.
    Vitali, F.
    Hirschmann, S.
    Koch, F.
    Ramming, A.
    Zundler, S.
    Nagore, D.
    Uter, W.
    Neurath, M. F.
    Atreya, R.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S416 - S416
12345